Gene Editing Optibrium appoints Steve Yemm as Chief Commercial Officer Posted on January 17, 2023 by Editorial Staff New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team. Share on FacebookTweetFollow us Editorial Staff The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
